Anti-ADAR2 antibody

[STJ91484] Download PDF Print Data Sheet

* Required Fields

£0.00
Product name Anti-ADAR2 antibody
Short Description Rabbit polyclonal against ADAR2
Description Rabbit polyclonal to ADAR2.
Applications ELISA, IHC-p, WB
Dilution range WB 1:500-1:2000
IHC 1:100-1:300
ELISA 1:20000
Specificity ADAR2 polyclonal antibody detects endogenous levels of ADAR2 protein.
Protein Name Double-Stranded Rna-Specific Editase 1
Rna-Editing Deaminase 1
Rna-Editing Enzyme 1
Dsrna Adenosine Deaminase
Immunogen Synthesized peptide derived from human ADAR2
Immunogen Region 450-530 aa, Internal
Storage Instruction Store at-20°C, and avoid repeat freeze-thaw cycles.
Note FOR RESEARCH USE ONLY (RUO).
Host Rabbit
Clonality Polyclonal
Reactivity Human, Mouse, Rat
Conjugation Unconjugated
Concentration 1 mg/ml
Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Isotype IgG
Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Gene ID 104
Gene Symbol ADARB1
Molecular Weight 80 kDa
Database Links HGNC:226
OMIM:601218
Alternative Names Anti-Double-Stranded Rna-Specific Editase 1 antibody
Anti-Rna-Editing Deaminase 1 antibody
Anti-Rna-Editing Enzyme 1 antibody
Anti-Dsrna Adenosine Deaminase antibody
Anti-ADARB1 ADAR2 DRADA2 RED1 antibody
Function Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins.pre-mRNA splicing by altering splice site recognition sequences.RNA stability by changing sequences involved in nuclease recognition.genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication.and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis.
Cellular Localization Nucleus
Nucleolus
Shuttles Between Nucleoli And The Nucleoplasm
Tissue Specificity Highly expressed in brain and heart and at lower levels in placenta. Fair expression in lung, liver and kidney. Detected in brain, heart, kidney, lung and liver (at protein level). Isoform 5 is high expressed in hippocampus and colon. Isoform 5 is expressed in pediatric astrocytomas and the protein has a decreased RNA-editing activity. The decrease in RNA editing correlates with the grade of malignancy of the tumors, with the high grade tumors showing lower editing is seen.
Swiss-Prot Key RED1_HUMAN
Bad Good
Enter the code in the box below:

Ask us a question

No questions yet. Be the first to ask the question!

Tags:

Use spaces to separate tags. Use single quotes (') for phrases.